Jarden Research Downgrades Aroa Biosurgery to Neutral From Overweight, Adjusts Price Target to AU$0.71 From AU$1
Jarden Research Downgrades Aroa Biosurgery to Neutral From Overweight, Adjusts Price Target to AU$0.71 From AU$1
Jarden研究將Aroa Biosurgery評級從超額增持下調至中立，將目標價從澳元1元調整爲0.71澳元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間